Cel Sci Corporation New (CVM)

So,.. no new news yet again.

$CVM ALERT
https://stockscan.io/stocks/CVM

$CVM Huge news ~ CEL-SCI Enters Strategic Agreement with Amarox for the Registration, Commercialization, and Distribution of Multikine in Saudi Arabia



50%/50% revenue sharing agreement for Multikine sales in Saudi Arabia upon receipt of Breakthrough Medicine Designation

Amarox to act as the local regulatory representative and lead all communications with the Saudi Food and Drug Authority (SFDA)

Amarox ranked #1 for SFDA applications for critical and unavailable medicine for 3 consecutive years

Amarox to be exclusive commercial distributor of Multikine in Saudi Arabia, upon SFDA approval, with optional expansion to GCC countries

Immunotherapy is among the fastest-growing segments in the Saudi cancer market, projected to reach $2.7 billion by 2033


https://finance.yahoo.com/sectors/healthcare/articles/cel-sci-enters-strategic-agreement-120000300.html

CEL-SCI Reports Fiscal Second Quarter 2026 Results
https://finance.yahoo.com/sectors/healthcare/articles/cel-sci-reports-fiscal-second-120000650.html

Robot is a d list celebrity who lost big on both nwbo and cvm

Yesterday's daily short sale volume was 36.66% (as reported by FINRA) and the shorts are still manipulating the market but the PPS went up 8.33%! The short borrow fee is at 241.6% and 708'400 shares are currently shorted — that is 8.4% of the Float!! Furthermore, the short shares availability is 350'000. Cel-Sci's CEO Geert Kersten bought another 100'000 shares on May 13, 2026, sending a message to investors. With the pending SFDA decision and the new strategic agreement with Amarox, we are expecting news in the coming days and a potential sale of Multikine in SA in the coming months. I am so happy for all the cancer patients who will hopefully soon benefit from Multikine! GLTAL!!

Clown

They have been riding on Mulkitine for 20 years or more. I don't own any shares now but I did in the 1990s. Just saying, play the trade.

Nice to see Kirsten stepped up and bought 100k shares on the offering. Looks like they can stay in business a little longer. Let's hope they use the money wisely and the tests are successful.

CEL-SCI Announces Closing of Public OfferingMay 13, 2026 3:00 PM
Business Wire CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the closing of its best-efforts public offering of 6,000,000 shares of its common stock. Each share of common stock was sold at a public offering price of $1.20 per share. Total gross proceeds from the offering, before deducting the placement agent’s fees and other offering expenses, were approximately $7.2 million. The Company intends to use the net proceeds from the offering to fund the continued development of Multikine*, general corporate purposes, and working capital. ThinkEquity acted as the sole placement agent for the offering. A registration statement on Form S-1 (File No. 333-295168) relating to the shares was filed with the Securities and Exchange Commission (“SEC”) and became effective on May 11, 2026. This offering was made only by means of a prospectus. Copies of the final prospectus may be obtained from ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About CEL-SCI Corporation CEL-SCI believes that boosting a patient’s immune system before surgery, radiotherapy and chemotherapy have damaged it, should provide the greatest possible impact on survival. Multikine is designed to help the immune system "target" the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. Multikine (Leukocyte Interleukin, Injection), given right after diagnosis and before surgery, has been dosed in over 740 patients and received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma (cancer) of the head and neck. The Company has operations in Vienna, Virginia, and near/in Baltimore, Maryland. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words "intends," "believes," "anticipated," "plans" and "expects," and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI's filings with the Securities and Exchange Commission, including but not limited to its report on Form 10-K for the year ended September 30, 2025. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. * Multikine (Leukocyte Interleukin, Injection) is the trademark that CEL-SCI has registered for this investigational therapy. This proprietary name is subject to FDA review in connection with the Company's future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. View source version on businesswire.com: https://www.businesswire.com/news/home/20260513189882/en/ COMPANY CONTACT:
Gavin de Windt
CEL-SCI Corporation
(703) 506-9460 Original: CEL-SCI Announces Closing of Public Offering

Sushi was right

Prove me wrong

Before the offering of 6 million shares, CVM has 8.5m shares outstanding. It has traded 50% of the outstanding shares today as of noon. The offer closes tomorrow. Who is paying 1.25 for a stock currently trading at $1? Current market cap is under $10M. Saudis are the naughties.

ThinkEquity is acting as the sole placement agent for the offering.

ThinkEquity LLC has been associated with various allegations of broker fraud, negligence, and unsuitable investment recommendations, according to regulatory filings. Investors have filed complaints against ThinkEquity advisors regarding breaches of fiduciary duty, and specific brokers like William Baquet and Ben Sutak have faced lawsuits or complaints.Key Aspects of ThinkEquity Related Allegations:Broker Misconduct: BrokerCheck records highlight complaints against ThinkEquity LLC brokers involving allegations of fraud, misrepresentation, breach of contract, and breach of fiduciary duty.Suitability Complaints: Advisors have faced complaints regarding the recommendation of unsuitable investments.Specific Cases:Ben Sutak: Received a $296K complaint, according to Carlson Law.William Baquet: Involved in a civil suit alleging fraud.Brian Vera: Broker linked to claims of fraud and elder abuse

AI Overview "Death spiral" financing, or toxic convertible debt, is a structured financing method where investors provide capital to often-distressed companies in exchange for convertible debt. This debt can be converted into common stock at a significant discount to the market price, often leading to a massive increase in share count, a plummeting stock price, and potential bankruptcy for the company.Based on your query, here is an overview of the mechanics, risks, and context surrounding this type of financing:Mechanics of the "Death Spiral"Convertible Debt: Investors receive convertible preferred stock or debentures.Discounted Conversion: The debt is converted into shares at a discount (e.g., 80% of the lowest trading price over a preceding period).Short Selling: To secure immediate profits, investors often short sell the company's common stock.Dilution and Downward Pressure: As investors convert debt to cover their short positions, new shares flood the market, driving the stock price down.The Cycle: Because the conversion price is linked to the stock price, a falling stock price means more shares are issued, causing further dilution and further price drops.Risks and ConsequencesSevere Dilution: Existing shareholders see their stakes severely diluted."R.I.P." for the Company: While not always the sole cause, this financing can hasten the failure of a company already in distress.Loss of Control: Companies may lose control of their equity, and in some cases, the lender essentially gains control.Limited Financing Options: The toxic nature of these deals can make it impossible for the company to raise capital from other sources.Context on "Toxic" FinancingTargeted Companies: Such financing is usually sought by microcap or small-cap companies with limited capital options, often experiencing, or on the brink of, financial trouble.Prevalence: According to a report from August 2024, the microcap market faces "unprecedented challenges" from this type of financing and aggressive short-selling.Regulatory Scrutiny: The SEC has investigated such financing, sometimes referred to as "death spiral" or "toxic" because of its destructive impact on shareholder value.Note: While the query mentions a specific firm, "death spiral" financing is a widespread, high-risk financial instrument used by various investors. The information above explains the mechanism itself based on general financial reporting.

today announced the pricing of a best-efforts public offering of 6,000,000 shares of its common stock at an offering price of $1.20 per share

Laughing at you guys

Sushi was right

CEL-SCI Corporation Announces Pricing of Public OfferingMay 11, 2026 8:11 PM
Business Wire CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the pricing of a best-efforts public offering of 6,000,000 shares of its common stock at an offering price of $1.20 per share. Total gross proceeds from the offering, before deducting the placement agent’s fees and offering expenses, are expected to be approximately $7.2 million. The offering is expected to close on May 13, 2026, subject to satisfaction of customary closing conditions. The Company intends to use the proceeds for the continued development of Multikine*, general corporate purposes, and working capital. ThinkEquity is acting as the sole placement agent for the offering. A registration statement on Form S-1 (File No. 333-295168) relating to the shares was filed with the Securities and Exchange Commission (“SEC”) and became effective on May 11, 2026. This offering is being made only by means of a prospectus. Copies of the final prospectus, when available, may be obtained from ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004. The final prospectus will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About CEL-SCI Corporation CEL-SCI believes that boosting a patient’s immune system before surgery, radiotherapy and chemotherapy have damaged it, should provide the greatest possible impact on survival. Multikine is designed to help the immune system "target" the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. Multikine (Leukocyte Interleukin, Injection), given right after diagnosis and before surgery, has been dosed in over 740 patients and received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma (cancer) of the head and neck. The Company has operations in Vienna, Virginia, and near/in Baltimore, Maryland. Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words "intends," "believes," "anticipated," "plans" and "expects," and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI's filings with the Securities and Exchange Commission, including but not limited to its report on Form 10-K for the year ended September 30, 2025. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. * Multikine (Leukocyte Interleukin, Injection) is the trademark that CEL-SCI has registered for this investigational therapy. This proprietary name is subject to FDA review in connection with the Company's future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. View source version on businesswire.com: https://www.businesswire.com/news/home/20260511186764/en/ COMPANY CONTACT:
Gavin de Windt
CEL-SCI Corporation
(703) 506-9460 Original: CEL-SCI Corporation Announces Pricing of Public Offering

buy the rumor sell the news

After hours down another 0.16 to $1.25. Wonder when old Geert gonna call for another R/S. You would think good news would mean going up but looks like investers are onto Geert's moves.

After hours down another 0.16 to $1.25. Wonder when old Geert gonna call for another R/S. You would think good news would mean going up but looks like investers are onto Geert's moves.

Why when we get supposedly good news we go down 0.29 today

Anyone have any info about what is going on with the anal warts or the Leaps programs. Haven't heard anything for quite a while?

It's good to get an update from the Saudi end, and on some details about potential revenue. Here's hoping that Amarox has a better influence on the SFDA and this time the approvals go through.

In the meantime, how about getting the confirmatory trial started?

🚨 $CVM ON HIGH ALERT 🚨

CEL-SCI just signed a strategic partnership + distribution agreement with Amarox for Multikine in Saudi Arabia. 🧬🌍 https://wix.to/iZmbcFV

Big catalyst stack:

✅ Amarox to lead SFDA regulatory communications
✅ Exclusive Saudi distribution rights upon approval
✅ 50/50 net revenue split in Saudi Arabia
✅ Optional expansion to GCC markets
✅ CEL-SCI retains global Multikine IP + manufacturing rights
✅ Multikine targets head & neck cancer before surgery
✅ Breakthrough Medicine Designation pathway in focus
Saudi Arabia + potential GCC expansion could open a major commercial/regulatory pathway for $CVM’s Multikine story. 👀📈
DYOR | 🚨StockOnHighAlert🚀 @TheBullRunShow

OK - decent volume for a change, and we're up about 18% at the moment. Can't find any news behind this though.

The previous clinical tests showed it worked if chemo was not used. Geert kept this data quiet for months where we stayed at $25 for months, once he stated multikine did not work when chemo was used we went to $0.20 and he made the 1 for 30 R/S. He should have pushed to be used first and with no response then chemo, some even he said were cured, but he wants to keep his personal ATM going.

$CVM CEL-SCI believes that boosting a patient’s immune system while it is still intact should provide the greatest possible impact on survival. Multikine is designed to help the immune system "target" the tumor before surgery, radiation and chemotherapy because that is the time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor.

$CVM- “CEL-SCI has a dedicated and passionate team that believes boosting a patient’s immune system while it is still intact should provide the greatest possible impact on survival when it comes to cancer immunotherapy.”
https://cel-sci.com/

$CVM #nasdaq CEL-SCI Corporation is a biotechnology firm focused on developing immunotherapies.

REVERSE SPLIT INCOMING

It’s the c list celebrity!

How’s your nwbo and cvm doing

Ha

Its the Grift that never ends.

S1 filed again

https://archive.fast-edgar.com/20260501/A8BOM22CZ222P2ZF222A2MZIGNAQZS22Z282/

S1 filed again

https://archive.fast-edgar.com/20260501/A8BOM22CZ222P2ZF222A2MZIGNAQZS22Z282/

It’s out on SFDA website

Cvm is not approved

Laughing at The Q

Well, here's team member number two of the promo team. You guys must be getting paid extra

🚨 $CVM ON HIGH ALERT 🚨

CEL-SCI’s Multikine cancer immunotherapy story could be heating up: https://wix.to/mW0lbD7

✅ 212-patient FDA confirmatory registration study
✅ Head & neck cancer focus
✅ FDA Orphan Drug designation
✅ Prior Phase III survival data cited by company
✅ Saudi Arabia Breakthrough Medicine pathway
✅ High-risk biotech catalyst setup

$CVM could be one to watch as Multikine advances toward key regulatory milestones.

$CVM is garbage and they've agreed to all sorts of death spiral financing in the past that will ever keep them down. They've had how many reverse splits already?
Wait for a group of investors to lose all their money, then rinse and repeat. And this time they've hired a promotions group to help.

$CVM #nasdaq CEL-SCI Corporation is a biotechnology firm focused on developing immunotherapies.

Had to figure that they were going to do some sort of fundraise,... Here's hoping it's enough to get the confirmatory study running.

the strategy is to continue on as a going concern

Notes on the S-1 Filing.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box: (Box Checked)

The information contained in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.


We are offering on a best efforts basis 3,440,367 shares of common stock of CEL-SCI Corporation based on an assumed public offering price of $4.36 per share (which is the last reported sales price of our shares on the NYSE American on April 14, 2026).



Our shares of common stock are traded on the NYSE American under the symbol CVM. The actual public offering price per share sold in this offering will be determined between us and the placement agent based on market conditions at the time of pricing and may be at a discount to the current market price. Therefore, the assumed public offering price used throughout this prospectus may not be indicative of the final offering price.



We are also offering to those purchasers, if any, whose purchase of common stock in this offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock immediately following the consummation of this offering, the opportunity to purchase, if the purchaser so chooses, pre-funded warrants (each a “Pre-Funded Warrant”) exercisable at an exercise price of $0.0001 per share. The purchase price of each Pre-Funded Warrant is equal to the price per share of common stock being sold to the public in this offering, minus $0.0001. The Pre-Funded Warrants will be immediately exercisable and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full.



For each Pre-Funded Warrant we sell, the number of shares of common stock we are offering will be decreased on a one-for-one basis. This offering also includes the shares of common stock issuable from time to time upon exercise of the Pre-Funded Warrants.



We have engaged ThinkEquity LLC (the “placement agent”) to act as our exclusive placement agent in connection with this offering. The placement agent has agreed to use its reasonable best efforts to arrange for the sale of the securities offered by this prospectus. The placement agent is not purchasing or selling any of the securities we are offering and the placement agent is not required to arrange the purchase or sale of any specific number or dollar amount of securities. We have agreed to pay placement agent fees to the placement agent as set forth in the table below, which assumes that we sell all of the securities offered by this prospectus. Since we will deliver the securities to be issued in this offering upon our receipt of investor funds, there is no arrangement for funds to be received in escrow, trust or similar arrangement. There is no minimum offering requirement as a condition of closing of this offering. Because there is no minimum offering amount required as a condition to closing this offering, we may sell fewer than all of the securities offered, which may significantly reduce the amount of proceeds received by us, and investors in this offering will not receive a refund in the event that we do not sell an amount of securities sufficient to pursue our business goals described in this prospectus. In addition, because there is no escrow account and no minimum offering amount, investors could be in a position where they have invested in our company, but we are unable to fulfill all of our contemplated objectives due to a lack of interest in this offering. Further, any proceeds from the sale of securities offered by us will be available for our immediate use, despite uncertainty about whether we would be able to use such funds to effectively implement our business plan. See the section entitled “Risk Factors” for more information. We will bear all costs associated with the offering. See “Plan of Distribution” on page S-37 of this prospectus for more information regarding these arrangements.

A Public Offering in Recent S-1 filings was announced at the time of the filing. Of course, the share price fell at the announcement. After the decline CVM then announced the Offering Price which caused an additional decline in the Stock. Don't know what the strategy is this time.

$CVM - #CVM #nasdaq CEL-SCI Corporation is a biotechnology firm focused on developing immunotherapies.

Been here 15+ years thru 3 R/S
After P3 we went to $45 one dsy then stayed at $25 for months when he said there was positive results, some cured. But for months Geert held out on the total data that he kept stalling. When he finally stated it did not work when chemo was used we fell like a rock. Instead of trying to go to the FDA stating using multikine first and if no improvement start chemo he said would have a new P3. Seems like he likes it the way it is without the costof manufacturing, distributing, etc and just likes reaping in what he can by keeping his scam going.

Geert needs to refill his private ATM

Boy. This aged well Joe

$CVM serious question for bulls:

Huge Offering

If the Saudi / SFDA deal is really right around the corner…

why are they filing an S-1 with:
• “going concern” language
• ~$13M raise
• heavy dilution
• best-efforts structure (no guaranteed demand)

You don’t do a dilutive survival raise right before a revenue-generating deal.

If Saudi were:
- imminent
- credible
- bringing in cash

👉 this raise would be smaller, structured, or not needed at all.

Instead, management is telling you (without saying it):

they need cash now — not later

Saudi might be a story.

This filing is reality.

Follow the money, not the narrative.

Yep,... That was somewhat surprising.